Novel ocular hypotensive drug meets endpointsNetarsudil ophthalmic solution 0.02% met its primary and secondary efficacy endpoints in a third phase III trial investigating its non-inferiority to timolol maleate 0.05% for IOP lowering. Laser system offers multiple treatments in single device January 01, 2017By Laird HarrisonNew laser technology in a single device offers multiple treatment platforms, including SLT for glaucoma, laser vitreolysis for floaters, capsulotomy, and iridotomy. Exploring risk, reward in trabecular bypass, suprachoroidal devices January 01, 2017By John Berdahl MDThough much focus for stents has been in the trabecular meshwork, many companies are currently developing suprachorodial devices, which are in various stages of FDA review. Intracameral prostaglandin analogue therapy delivers durable benefitFive patients receiving an extended-release travoprost delivery system (ENV515, Envisia Therapeutics) in the anterior chamber have ongoing IOP-lowering with follow-up to 9 months in an ongoing study. How oral and dental hygiene plays a role in glaucomaIn the past couple of years, there has been discussion regarding dental and oral health—specifically the oral biomicrome—as possibly having a relationship to glaucoma. How macular OCT scanning affects glaucoma evaluationLet’s examine what this specific (and separate) scan pattern can offer diagnostically 16 most popular stories of 2016 December 21, 2016By Jolie HigaziHere is your roundup of what made top news in 2016! 6 things PCPs should know about glaucoma December 19, 2016By Beth HertzGlaucoma is a leading cause of blindness, a problem which is made even more serious by the fact that many patients do not notice any symptoms until it is too late to prevent permanent blindness. Looking back at 2016Before the new year gets too far along, let’s take a brief look at the happenings in the pages of Optometry Times during 2016.